H. Barnett

Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors.

P. Grandi, A. Michon, Christina Rau, 2015, Journal of medicinal chemistry.

The Optimisation of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding Mode.

P. Bamborough, R. Prinjha, C. Chung, 2020, Journal of medicinal chemistry.

Aiming to Miss a Moving Target: Bromo and Extra Terminal Domain (BET) Selectivity in Constrained ATAD2 Inhibitors.

P. Grandi, A. Michon, Christina Rau, 2018, Journal of medicinal chemistry.

GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins.

P. Grandi, P. Bamborough, R. Prinjha, 2020, Journal of medicinal chemistry.

Aryl aminopyrazole benzamides as oral non-steroidal selective glucocorticoid receptor agonists.

H. T. Jones, James M. Woolven, I. McLay, 2009, Bioorganic & medicinal chemistry letters.

Discovery of a potent series of non-steroidal non α-trifluoromethyl carbinol glucocorticoid receptor agonists with reduced lipophilicity.

I. McLay, Hawa Diallo, I. Uings, 2011, Bioorganic & medicinal chemistry letters.

Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment Screening.

Darren L. Poole, Tony W Dean, I. Wall, 2020, Journal of medicinal chemistry.

GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain

David J. Fallon, P. Grandi, A. Michon, 2016, ACS medicinal chemistry letters.